Search company, investor...

Founded Year

2012

Stage

Grant - IV | Alive

Total Raised

$465.13M

Valuation

$0000 

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-117 points in the past 30 days

About Visby Medical

Visby Medical develops polymerase chain reaction (PCR) based diagnostic tests for the detection of infectious diseases. The company offers medical solutions for sexual health tests, respiratory health tests, and other infectious diseases. It was formerly known as Click Diagnostics. The company was founded in 2012 and is based in San Jose, California.

Headquarters Location

3010 North First Street

San Jose, California, 95134,

United States

833-468-4729

Loading...

Loading...

Expert Collections containing Visby Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Visby Medical is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,249 items

Visby Medical Patents

Visby Medical has filed 35 patents.

The 3 most popular patent topics include:

  • medical tests
  • molecular biology
  • blood tests
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/22/2021

7/16/2024

Molecular biology, Small nuclear RNA, Medical tests, RNA, Biotechnology

Grant

Application Date

10/22/2021

Grant Date

7/16/2024

Title

Related Topics

Molecular biology, Small nuclear RNA, Medical tests, RNA, Biotechnology

Status

Grant

Latest Visby Medical News

PCR Technologies Market Share Worth $24.52 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

Oct 17, 2024

News provided by Share this article Share toX The PCR Technologies Market size is expected to reach US$ 24.52 billion by 2030 from US$ 13.10 billion in 2022 to record a CAGR of 8.2% from 2022 to 2030. NEW YORK, Oct. 17, 2024 /PRNewswire/ -- According to The Insight Partners study on the Global  PCR Technologies Market  is recording significant growth owing to the surging incidences of infectious diseases and genetic disorders. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the PCR technologies market encompasses an array of platforms and services that are expected to gain prominence in the coming years. Download Sample Report: https://www.theinsightpartners.com/sample/TIPRE00003069/ Competitive Strategy and Development Key Players: A few major companies operating in the PCR technologies market include Thermo Fisher Scientific Inc., Promega Corp, QIAGE NV, bioMerieux SA, Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Becton Dickinson and Co, Atila Biosystems Inc, Takara Bio Inc, Standard BioTools Inc, Agilent Technologies Inc, Visby Medical Inc, and Ellume Ltd. Trending Topics: Digital PCR (dPCR), next-generation sequencing (NGS) integration, rapid PCR method, CRISPR-Cas9 and PCR, multiplex PCR, PCR in point-of-care testing, PCR in infectious disease surveillance, automated PCR platforms, among others. Global Headlines on PCR Technologies "Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges." "Stilla Technologies Partners with Niba Labs to accelerate the development of advanced digital PCR assays for cell and gene therapy, strengthen industry research, and expand analytical testing." "QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers." Identify the Key Trends Affecting This Market - Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00003069/ Overview of Report Findings Market Growth: The PCR technologies market is expected to reach a value of US$ 24.52 billion by 2030 from US$ 13.10 billion in 2022, at a CAGR of 8.20% from 2023 - 2030. PCR is a molecular technique that makes millions of copies of a particular DNA segment through the amplification of specific sequences. It has proven as a valuable procedure in numerous applications, ranging from genetic research to medical diagnostics, forensic science, and cloning. Rising Investments and Funds for Gene Synthesis: Gene synthesis is the most accepted tool in the field of recombinant DNA technology employed for recombinant protein production. It includes PCR technology for gene amplification as well as quantification purposes. In 2021, Camena Bioscience, a synthetic biology startup that supplies genes to the biotechnology and pharmaceutical sectors, completed a US$ 10 million Series A funding round headed by Mercia. With the additional funds, the company plans to expand its operations and continue developments in gene synthesis by upgrading its ground-breaking DNA synthesis platform. Several companies in the PCR technologies market have also increased their research and development funds for the enhancement of gene synthesis techniques. Increasing Adoption of PCR Methods in Emerging Countries: Molecular techniques such as PCR have evolved as diagnostic tools in recent years. The technique is regarded as an essential research and diagnostic tool since it allows medical practitioners to diagnose a broad spectrum of infectious disorders with accuracy. In PCR, a single DNA strand can produce millions of copies of itself. The technique also makes early disease diagnosis possible, which makes it crucial in local and global disease control efforts. Moreover, PCR is widely accepted worldwide due to the reproducibility of results, which are often comparable across labs. PCR methods are becoming common in developing nations. They are increasingly being employed in clinical microbiology, allied fields, parasitology, biotechnology, and virology. Thus, the burgeoning application of dPCR and qPCR in developing countries is expected to create lucrative opportunities in the PCR technologies market during the forecast period. Geographic Insights: In 2022, North America led the market with a substantial revenue share, followed by Europe and APAC, respectively. Asia Pacific is expected to record the highest CAGR during the forecast period. Market Segmentation Based on technology, the PCR technologies market is segmented into real-time PCR, conventional PCR, reverse transcription PCR, digital PCR, multiplex RT PCR, hot start PCR, and others. The real-time PCR segment held the largest market share in 2022. By offering, the PCR technologies market is segmented into reagents and consumables, instruments, and software and services. The reagents and consumables segment held the largest share of the market in 2022. In terms of application, the PCR technologies market is divided into gene expression analysis, genetic sequencing, genotyping, nucleic acid synthesis, standard validation, point-of-care diagnostics, environmental application, and others. The genetic sequencing segment held the largest share of the market in 2022. In terms of end user, the PCR technologies market is divided into hospitals and diagnostic centers, academia and research institutes, pharmaceutical and biotechnology companies, and others. The hospitals and diagnostic centers segment held a larger share of the PCR technologies market in 2022. The PCR technologies market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Purchase Premium Copy of Global PCR Technologies Market Growth Report (2021-2031) at: https://www.theinsightpartners.com/buy/TIPRE00003069/ Conclusion Advancements in molecular biology, increased demand for rapid diagnostic solutions, and expanding applications of PCR technology in the healthcare research and environment sectors are accelerating growth and innovation in the PCR technology market. Digital PCR, multiplexing, and next-generation sequencing integration contribute to accuracy in genetic analysis. The acceptance of personalized medicine and point-of-care testing would fuel further expansion in the PCR technologies market. Moreover, automated systems and user-friendly software for primer design would automate the process, and make research and clinical use accessible to all. Stakeholders in the PCR technology marketplace plan to focus on all emerging trends and innovations to fully tap its potential to address modern-day scientific and medical problems. The report from The Insight Partners, therefore, provides several stakeholders—including component providers, system technology integrators, and system manufacturers—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. Obtain Analysis of Key Geographic Markets - Download Report PDF: https://www.theinsightpartners.com/sample/TIPRE00003069/ PCR (Polymerase Chain Reaction) is a crucial tool in clinical settings due to its ability to amplify specific DNA and RNA sequences, enabling rapid and accurate detection of genetic variants, infectious diseases, and biomarkers. This molecular biology technique has revolutionized research, diagnostics, and various other applications. The increasing prevalence of chronic diseases and advancements in genomic research have further driven the demand for PCR-based diagnostics. As a result, PCR plays a key role in areas such as early detection of diseases, genetic testing, and the identification of pathogens. Technological advancements in PCR, including automation, integration with software, and improvements in instruments and chemicals, have led to increased performance, sensitivity, and efficiency. These developments have made PCR workflows faster, more accurate, and cost-effective, contributing to the expanding market. Real-time PCR (qPCR) and portable systems, for example, have enhanced diagnostic capabilities, making PCR applicable in remote and point-of-care settings. Overall, PCR's continuous evolution and its diverse applications across healthcare, agriculture, and research have cemented its importance in modern molecular diagnostics. Require A Diverse Region or Sector? Customize Research to Suit Your Requirement: https://www.theinsightpartners.com/inquiry/TIPRE00003069/ Government and federal agencies worldwide recognize the role of quantitative polymerase chain reaction (qPCR) and dPCR products in genome-based research. In February 2019, Genome Canada partnered with the federal government of Canada and various provincial governments, companies, and research groups. Genome Canada received ~US$ 42.6 million through these partnerships in funding for bioinformatics and human health genomics projects. Visby Medical, an infectious disease diagnostics company based in the US, obtained funding from the National Institutes of Health (NIH) in October 2020 for Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative. In 2021, Camena Bioscience, a synthetic biology startup that supplies genes to the biotechnology and pharmaceutical sectors, completed a US$ 10 million Series A funding round headed by Mercia. With the additional funds, the company expanded its operations and continued the development of its ground-breaking DNA synthesis platform—gSynth. The technology platform and other related resources help the company accelerate the development of gene synthesis. Several companies have also increased their research and development funds to enhance gene synthesis. In 2020, EVONETIX LTD, a synthetic biology startup that creates a desktop platform for high-fidelity, rapid, and scalable gene synthesis, announced the completion of its Series B financing round. The company, led by new investor Foresite Capital, raised US$ 30 million (£23 million) in this round. Therefore, increasing financial support for research and development in disease-specific genomics propels the demand for PCR technologies. Related Report Titles: Microcarriers Market Size, Scope, Growth & Outlook 2030 Bioreactors Market Analysis, Size, Share, Growth, Trends, and Forecast by 2030 Bioproduction Market Size Report | Global Share & Growth Outlook 2030 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur

Visby Medical Frequently Asked Questions (FAQ)

  • When was Visby Medical founded?

    Visby Medical was founded in 2012.

  • Where is Visby Medical's headquarters?

    Visby Medical's headquarters is located at 3010 North First Street, San Jose.

  • What is Visby Medical's latest funding round?

    Visby Medical's latest funding round is Grant - IV.

  • How much did Visby Medical raise?

    Visby Medical raised a total of $465.13M.

  • Who are the investors of Visby Medical?

    Investors of Visby Medical include CARB-X, John Doerr, Pitango Venture Capital, Artiman Ventures, Blue Water Life Science Advisors and 22 more.

  • Who are Visby Medical's competitors?

    Competitors of Visby Medical include Sense Biodetection and 1 more.

Loading...

Compare Visby Medical to Competitors

N
Nostics

Nostics is a company focused on the development of diagnostic technology in the healthcare industry. The company offers a platform that provides rapid, accessible, and affordable testing for bacteria and fungi, utilizing advanced nanotechnology, AI, and Raman spectroscopy in a portable device. Nostics primarily serves the healthcare sector, with solutions designed for primary care, diagnostic labs, and research and biopharma. It is based in Amsterdam, Netherlands.

bioMerieux Logo
bioMerieux

bioMerieux specializes in in vitro diagnostics within the healthcare sector, focusing on the development and manufacturing of diagnostic tests. The company offers a broad range of products that enable rapid and accurate detection of infectious diseases, antimicrobial resistance, and food safety concerns, as well as solutions for pharmaceutical quality control. These products serve various sectors including healthcare, food industry, and pharmaceuticals. It was founded in 1963 and is based in Marcy L'Etoile, France.

O
Oxford Nanopore Technologies

Oxford Nanopore Technologies specializes in deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing technology within the biotechnology sector. The company offers products and solutions for DNA and RNA sequencing, including library preparation, sequencing devices, flow cells, and data analysis tools. Its products enable the analysis of genetic material for research in areas such as microbiology, human genetics, cancer, and environmental studies. It was founded in 2005 and is based in Oxford, United Kingdom.

Cue Health Logo
Cue Health

Cue Health serves as a healthcare technology company specializing in diagnostic testing within the health sector. The company offers a portable molecular testing platform that provides lab-quality, actionable health insights quickly and conveniently. Cue Health primarily serves the healthcare industry, including clinics and individuals seeking at-home diagnostic solutions. It was founded in 2010 and is based in San Diego, California. In May 2024, Cue Health filed for bankruptcy.

L
Lucira Health

Lucira Health (NASDAQ: LDHX) develops disposable Point-of-Care molecular tests for the diagnosis of infectious diseases. It develops a testing platform that produces laboratory molecular testing using a battery-powered test. The tool helps to detect COVID-19 and influenza Types A and B diseases. The company was founded in 2013 and is based in Emeryville, California.

S
Sense Biodetection

Sense Biodetection operates as a molecular diagnostics company. It designs and develops proprietary molecular and device technologies. The company serves hospitals, urgent care, nursing homes, workplace and campus health, community health, and travel sectors. The company was founded in 2014 and is based in Abingdon, U.K. In February 2023, Sense Biodetection was acquired by Sherlock Biosciences. The terms of the transaction were not disclosed.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.